PepGen falls after US FDA puts partial hold on mid‑stage drug trial

Shares of drug developer PepGen PEPG.O fall 17% to $5.60 in extended trading

PEPG says the U.S. FDA has put a partial clinical hold on its mid‑stage trial of a rare muscle disease drug

The drug, PGN‑EDODM1, is being tested for myotonic dystrophy type 1, which causes progressive muscle weakness

Co says the health regulator's concerns relate to earlier lab and animal studies the company submitted

PEPG says it's working with the FDA to address the questions and will submit additional info

PEPG rose 72.7% in 2025